GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » PS Ratio

AVEO Pharmaceuticals (AVEO Pharmaceuticals) PS Ratio : 5.49 (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, AVEO Pharmaceuticals's share price is $15.00. AVEO Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $2.73. Hence, AVEO Pharmaceuticals's PS Ratio for today is 5.49.

Warning Sign:

AVEO Pharmaceuticals Inc stock PS Ratio (=5.49) is close to 1-year high of 5.49

The historical rank and industry rank for AVEO Pharmaceuticals's PS Ratio or its related term are showing as below:

AVEO' s PS Ratio Range Over the Past 10 Years
Min: 1.51   Med: 11.97   Max: 101.67
Current: 5.49

During the past 13 years, AVEO Pharmaceuticals's highest PS Ratio was 101.67. The lowest was 1.51. And the median was 11.97.

AVEO's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 8.92 vs AVEO: 5.49

AVEO Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2022 was $0.88. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $2.73.

During the past 12 months, the average Revenue per Share Growth Rate of AVEO Pharmaceuticals was 257.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 46.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 15.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was -22.50% per year.

During the past 13 years, AVEO Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 72.80% per year. The lowest was -75.60% per year. And the median was -33.90% per year.

Back to Basics: PS Ratio


AVEO Pharmaceuticals PS Ratio Historical Data

The historical data trend for AVEO Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals PS Ratio Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.02 38.65 3.33 20.53 3.62

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.08 3.62 3.14 2.86 3.01

Competitive Comparison of AVEO Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, AVEO Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's PS Ratio falls into.



AVEO Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

AVEO Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.00/2.733
=5.49

AVEO Pharmaceuticals's Share Price of today is $15.00.
AVEO Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


AVEO Pharmaceuticals  (NAS:AVEO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


AVEO Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus

AVEO Oncology Stockholders Approve Acquisition by LG Chem

By Stock market mentor Stock market mentor 01-06-2023

AVEO Oncology Stockholders Approve Acquisition by LG Chem

By GlobeNewswire GlobeNewswire 01-06-2023